Loading
companiesCompany
A2 Biotherapeutics
A2 Biotherapeutics is a US-based cell therapy company that leads 3 cancer trials in OnCo, testing the logic-gated CAR-T therapies A2B395, A2B530, A2B694 and A2B543 in colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma and renal cell carcinoma.
Also called: A2 Bio
Overview
A2 Biotherapeutics is a clinical-stage biotechnology company developing logic-gated CAR T-cell therapies on its Tmod platform, designed to distinguish tumour cells from normal cells. Its clinical programmes include A2B395 (EGFR), A2B694 and A2B543 (mesothelin) and A2B530 (CEA). On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06682793 (phase 1/2, A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T,...), NCT05736731 (phase 1/2, A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Particip...) and NCT06051695 (phase 1/2, A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T,...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
- TargetSETDB1
Shares Mesothelioma, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- TrialTT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Mesothelioma, Renal cell carcinoma, Non-small-cell lung cancer.
- TargetERCC1
Shares Mesothelioma, Ovarian cancer, Non-small-cell lung cancer.
- PersonMichael Boyer
Shares Mesothelioma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- TrialVMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Shares Mesothelioma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- TrialA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Shares Mesothelioma, Renal cell carcinoma, Colorectal cancer.
- TargetNF2
Shares Mesothelioma, Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer.
- TargetNCOR1
Shares Mesothelioma, Head and neck squamous cell carcinoma, Colorectal cancer.
cancers
trials
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionA Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionA Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression